Frequency of Hospitalized Infections Is Reduced in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs after 2010

Table 3

The risk of infection in bDMARD uses analyzed with stepwise logistic regression.

Variable	Stepwise logistic regression
	Adjusted HR (95% CI)	value
Gender, male (%)	1.648 (0.669–3.897)	0.2705
Age at initiation of bDMARD/tsDMARD	1.033 (1.001–1.070)	0.0526
Number of previous bDMARD/tsDMARD uses	1.259 (0.797–1.931)	0.3137
Prophylaxis with an antituberculosis agent	2.502 (0.909–8.200)	0.0775
Comorbidities of chronic lung disease	5.342 (2.409–12.42)	<0.0001
Initiation of bDMARD/tsDMARD before 2010	4.266 (1.827–0.60)	0.0007

bDMARD: biological disease-modifying antirheumatic drug; tsDMARDs: targeted synthetic disease-modifying antirheumatic drug. .